CJC-1295 & Ipamorelin Blend (10mg)

CJC-1295 & Ipamorelin Peptide Blend – Long Description

Overview
The combination of CJC-1295 and Ipamorelin is a synergistic peptide blend designed to enhance endogenous growth hormone (GH) secretion by targeting different mechanisms in the anterior pituitary. Both peptides are classified as growth hormone secretagogues (GHSs). CJC-1295 mimics the action of growth hormone-releasing hormone (GHRH), while Ipamorelin selectively targets the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. This dual approach is theorized to amplify GH pulsatility and sustain elevated levels of insulin-like growth factor 1 (IGF-1), which mediates many anabolic effects in tissues.

Peptide Composition and Chemistry

• CJC-1295 includes four amino acid substitutions (positions 2, 8, 15, and 27) to enhance stability against enzymatic degradation, increase half-life, and improve receptor affinity.

• The DAC component (when included) binds to plasma proteins, extending peptide persistence and maintaining GH release.

• Ipamorelin selectively activates the GHS-R1a receptor in somatotrophs without stimulating other pituitary hormones like prolactin, minimizing off-target effects.

Mechanism of Action

1. CJC-1295

   • Binds GHRH receptors on somatotroph cells in the anterior pituitary.

   • Triggers conformational changes that activate G-proteins, inducing secondary messengers such as cAMP and IP3.

   • Activates protein kinases that phosphorylate transcription factors, influencing genes involved in GH synthesis.

   • Sustained GH release stimulates IGF-1 production in liver and peripheral tissues, supporting anabolic and regenerative functions.

2. Ipamorelin

   • Binds selectively to GHS-R1a receptors on pituitary and hypothalamic cells.

   • Activation of Gαq/11 proteins stimulates phospholipase C (PLC), generating IP3 and DAG.

   • IP3 increases calcium release from the endoplasmic reticulum; DAG activates protein kinase C (PKC).

   • These cascades facilitate GH exocytosis without affecting other anterior pituitary hormones.

3. Synergistic Action

   • Ipamorelin triggers rapid GH release within 1–2 hours post-administration.

   • CJC-1295 maintains prolonged GH elevation, creating a sustained pulsatile pattern.

   • The blend may enhance GH-mediated effects, including increased muscle protein synthesis, improved nitrogen balance, and positive lean mass gain.

Pharmacokinetics

• When combined, Ipamorelin initiates GH release while CJC-1295 sustains it over a prolonged period.

• This combination has been observed to increase GH secretion by 46–75% and IGF-1 levels by ~45% on average in clinical models.

Physiological Effects

• Muscle Hypertrophy: GH and IGF-1 stimulate fibroblast and myocyte proliferation, supporting lean tissue growth.

• Fat Metabolism: Enhanced lipolysis through GH-mediated pathways, potentially reducing adipose tissue.

• Bone Health: IGF-1 promotes osteoblast activity, enhancing bone density.

• Cellular Anabolism: Positive nitrogen balance, increased urea cycle efficiency, and support for organ protein synthesis.

• GH Pulsatility Restoration: Mimics natural endocrine rhythms, improving metabolic and physiological outcomes.

Research Findings

• Clinical trials demonstrate Ipamorelin’s rapid GH induction with short half-life, while CJC-1295 extends GH release.

• Studies suggest CJC-1295 may stimulate somatotroph cell proliferation, increasing pituitary RNA and GH mRNA expression.

• The peptide blend is under investigation for lean mass improvement, tissue regeneration, metabolic support, and aging-related research.

• Positive nitrogen balance studies indicate potential improvements in protein metabolism and anabolic efficiency in experimental models.

Applications

• Research in GH deficiency, aging, sarcopenia, and metabolic disorders.

• Studying anabolic effects on muscle, bone, and connective tissue.

• Investigating GH pulsatility restoration and IGF-1-mediated cellular regeneration.

Important Note: This peptide blend is for research purposes only and is not approved for therapeutic use in humans. Strict laboratory protocols should be followed.

References

1. Raun K, Hansen BS, Johansen NL, et al. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552

2. Jetté L, Léger R, Thibaudeau K, et al. Endocrinology. 2005;146(7):3052–3058. doi:10.1210/en.2004-1286

3. Khorram O, Laughlin GA, Yen SS. J Clin Endocrinol Metab. 1997;82(5):1472–1479

4. Henninge J, Pepaj M, et al. Drug Test Anal. 2010;2(11-12):647–650

5. Sinha DK, Balasubramanian A, et al. Transl Androl Urol. 2020;9(Suppl 2):S149–S159